Background And Purpose: Inguinal lymph node involvement is considered the most important prognostic risk factor for survival in vulvar cancer. However, controversy exists concerning the optimal adjuvant therapy for node-positive disease. This study sought to identify the optimal adjuvant therapy for each subset of women with node-positive disease.
Material And Methods: The National Cancer Database (NCDB) was queried to identify women with inguinal node positive vulvar cancer. Survival analysis was performed using log-rank test, the Kaplan-Meier estimates, and Cox proportional hazards to both clarify prognosis and identify the benefit of each treatment modality in individual subsets of women.
Results: A total of 2779 women with inguinal node positive vulvar cancer were identified. On multivariate Cox model hazard ratio, radiotherapy yielded a survival advantage for women with one positive node (HR 0.81, p = 0.027) and two or more positive nodes (HR = 0.59, p < 0.001). The addition of chemotherapy to radiotherapy yielded an incremental improvement in survival for women with 2 or more positive nodes (HR = 0.79, p = 0.022) but not women with 1 positive node (HR = 0.93, p = 0.605).
Conclusions: All patients with node positive disease benefited from radiotherapy. By contrast, only those with 2 or more positive nodes benefited from the addition of chemotherapy to radiotherapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.radonc.2018.03.023 | DOI Listing |
Int J Surg Case Rep
January 2025
Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, China; Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China. Electronic address:
Introduction And Importance: Cervical cancer is highly correlated with high-risk human papillomavirus (HPV) infection, accounting for approximately 70 % of cases. However, false-negative HPV test results can occur, complicating early detection.
Case Presentation: We introduce a rare case of cervical cancer with lung metastasis followed by vulvar metastasis.
Cureus
December 2024
Obstetrics and Gynaecology, Fernandez hospital, Hyderabad, IND.
Vulvar cancer is an uncommon malignancy in reproductive-aged women, and its occurrence during pregnancy is rare. This report presents a case of vulvar squamous cell carcinoma (VSCC) diagnosed perioperatively in a 35-year-old pregnant woman. The patient was incidentally found to have lichen sclerosis and a suspicious vulvar lesion during an emergency cesarean section.
View Article and Find Full Text PDFInt J Gynecol Cancer
January 2025
Hacettepe University, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine, Ankara, Turkey.
Background: Vulvar squamous cell carcinoma incidence is increasing, especially among women under 60, largely attributed to human papillomavirus infections. Precursor pre-invasive vulvar lesions are frequently underdiagnosed. Routine vulvar inspection during cervical cancer screening could offer an opportunity for the detection of these lesions.
View Article and Find Full Text PDFInfect Agent Cancer
January 2025
Shahid Beheshti University of Medical Sciences, Hamadan University of Medical Sciences, Hamadan, Iran.
Both women and men are now confronted with the grave threat of cancers caused by the human papillomavirus (HPV). It is estimated that 80% of women may encounter HPV over their lives. In the preponderance of cases involving anal, head and neck, oral, oropharyngeal, penile, vaginal, vulvar, and cervical malignancies, high-risk HPV (HR-HPV) is the causative agent.
View Article and Find Full Text PDFAnn Hematol
January 2025
Department of Obstetrics and Gynecology, The Helen Schneider Hospital for Women, Rabin Medical Center, Petach-Tikva, Israel.
Chronic Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT), affecting the female genital tract in 25-66% of the patients. This condition, referred to as Genital GVHD is an underdiagnosed gynecologic comorbidity, that can significantly impair quality of life. We aimed to describe the prevalence and management of genital GVHD following HSCT.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!